Eton Pharmaceuticals, Inc.
ETON
$58.86
$18.0644.27%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.03% | -5.25% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.03% | -5.25% | |||
| Cost of Revenue | 35.81% | -49.10% | |||
| Gross Profit | 3.88% | 58.20% | |||
| SG&A Expenses | 26.24% | 2.08% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 27.87% | -25.26% | |||
| Operating Income | -38.11% | 11,551.28% | |||
| Income Before Tax | 11.32% | 172.33% | |||
| Income Tax Expenses | 128.99% | -146.43% | |||
| Earnings from Continuing Operations | 4.79% | 176.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 4.79% | 176.96% | |||
| EBIT | -38.11% | 11,551.28% | |||
| EBITDA | -28.96% | 465.26% | |||
| EPS Basic | 3.45% | 176.85% | |||
| Normalized Basic EPS | -44.39% | 639.46% | |||
| EPS Diluted | -1.38% | 170.71% | |||
| Normalized Diluted EPS | -44.22% | 564.63% | |||
| Average Basic Shares Outstanding | 1.29% | 0.16% | |||
| Average Diluted Shares Outstanding | 0.97% | 16.18% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||